Foundry Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $19M | Sell |
748,723
-42,665
| -5% | -$1.12M | 1% | 30 |
|
|
2024
Q4 | $21M | Buy |
+791,388
| New | +$21.5M | 1.06% | 24 |
|
|
2022
Q3 | – | Sell |
-485,705
| Closed | -$25.5M | – | 326 |
|
|
2022
Q2 | $25.5M | Buy |
485,705
+44,260
| +10% | +$2.26M | 1.53% | 13 |
|
|
2022
Q1 | $22.9M | Sell |
441,445
-9,750
| -2% | -$506K | 1.17% | 24 |
|
|
2021
Q4 | $26.6M | Buy |
+451,195
| New | +$22.4M | 0.94% | 17 |
|
|
2021
Q2 | – | Sell |
-9,475
| Closed | -$343K | – | 421 |
|
|
2021
Q1 | $343K | Sell |
9,475
-512,965
| -98% | -$18.2M | 0.01% | 400 |
|
|
2020
Q4 | $19.2M | Sell |
522,440
-250,935
| -32% | -$9.2M | 0.75% | 28 |
|
|
2020
Q3 | $26.9M | Sell |
773,375
-5,227
| -0.7% | -$183K | 1.3% | 3 |
|
|
2020
Q2 | $24.2M | Sell |
778,602
-196,513
| -20% | -$6.68M | 1.18% | 7 |
|
|
2020
Q1 | $30.2M | Sell |
975,115
-136,378
| -12% | -$4.65M | 1.7% | 3 |
|
|
2019
Q4 | $41.3M | Buy |
1,111,493
+149,979
| +16% | +$5.34M | 1.56% | 3 |
|
|
2019
Q3 | $32.8M | Buy |
961,514
+255,796
| +36% | +$9.3M | 1.35% | 4 |
|
|
2019
Q2 | $29M | Buy |
705,718
+4,321
| +0.6% | +$172K | 1.14% | 7 |
|
|
2019
Q1 | $28.3M | Buy |
701,397
+3,373
| +0.5% | +$135K | 1.13% | 6 |
|
|
2018
Q4 | $28.9M | Buy |
698,024
+23,425
| +3% | +$972K | 1.3% | 5 |
|
|
2018
Q3 | $28.2M | Sell |
674,599
-47,570
| -7% | -$1.83M | 1.07% | 9 |
|
|
2018
Q2 | $24.9M | Buy |
722,169
+72,315
| +11% | +$2.47M | 1.02% | 7 |
|
|
2018
Q1 | $21.9M | Buy |
649,854
+222,720
| +52% | +$7.66M | 0.93% | 10 |
|
|
2017
Q4 | $14.7M | Buy |
+427,134
| New | +$14.6M | 0.61% | 43 |
|
|
2017
Q1 | – | Sell |
-637,526
| Closed | -$19.6M | – | 443 |
|
|
2016
Q4 | $19.6M | Sell |
637,526
-300,935
| -32% | -$9.19M | 0.85% | 9 |
|
|
2016
Q3 | $30.2M | Buy |
938,461
+89,248
| +11% | +$2.98M | 1.59% | 3 |
|
|
2016
Q2 | $28.4M | Buy |
849,213
+123,104
| +17% | +$3.93M | 1.61% | 1 |
|
|
2016
Q1 | $20.4M | Buy |
726,109
+42,432
| +6% | +$1.21M | 2.02% | 7 |
|
|
2015
Q4 | $20.9M | Buy |
+683,677
| New | +$21.5M | 1.74% | 7 |
|
|
2014
Q4 | – | Sell |
-16,342
| Closed | -$458K | – | 265 |
|
|
2014
Q3 | $458K | Sell |
16,342
-9,059
| -36% | -$254K | 0.04% | 214 |
|
|
2014
Q2 | $715K | Sell |
25,401
-1,476
| -5% | -$42.1K | 0.07% | 198 |
|
|
2014
Q1 | $819K | Buy |
+26,877
| New | +$801K | 0.08% | 205 |
|
Other funds holding PFE
TIM
Foundry Partners's PFE Position: Q1 2025 in Review
Foundry Partners reduced its Pfizer (PFE) stake by 5.4% in Q1 2025, selling an estimated $1.12M and leaving 748,723 shares worth $19M. The position accounts for 1% of the portfolio, ranked #30.
Foundry Partners first reported a position in PFE in Q1 2014 and has held it in 27 quarters since. The position peaked at $41.3M in Q4 2019. 2,930 funds tracked by Wall St. Rank hold PFE as of Q1 2025.
- Foundry Partners held 748,723 shares of Pfizer worth $19M as of Q1 2025.
- Foundry Partners sold 42,665 Pfizer shares in Q1 2025, an estimated $1.12M.
- Pfizer made up 1% of Foundry Partners's portfolio in Q1 2025, its #30 holding.
- Foundry Partners first reported a position in Pfizer in Q1 2014 and has held it in 27 quarters since.
- Foundry Partners's Pfizer position peaked at $41.3M in Q4 2019.
- 2,930 funds tracked by Wall St. Rank held Pfizer as of Q1 2025.
Based on Foundry Partners's 13F filing for Q1 2025, filed 5 May 2025.